Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 23 Thousand SEK | -88.67% |
| 2022 | 203 Thousand SEK | -50.12% |
| 2021 | 407 Thousand SEK | 1903.94% |
| 2020 | 20.31 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 284 Thousand SEK | 13.6% |
| 2024 Q3 | - SEK | -100.0% |
| 2024 Q1 | 250 Thousand SEK | 986.96% |
| 2023 Q2 | 911 Thousand SEK | -11.55% |
| 2023 FY | 23 Thousand SEK | -88.67% |
| 2023 Q4 | 23 Thousand SEK | -97.06% |
| 2023 Q1 | 1.03 Million SEK | 21.75% |
| 2023 Q3 | 781 Thousand SEK | -14.27% |
| 2022 FY | 203 Thousand SEK | -50.12% |
| 2022 Q4 | 846 Thousand SEK | -34.16% |
| 2022 Q3 | 1.28 Million SEK | 2419.61% |
| 2022 Q2 | 51 Thousand SEK | -66.67% |
| 2022 Q1 | 153 Thousand SEK | 0.0% |
| 2021 Q2 | 102 Thousand SEK | -96.41% |
| 2021 FY | 407 Thousand SEK | 1903.94% |
| 2021 Q3 | 152 Thousand SEK | 49.02% |
| 2021 Q4 | 153 Thousand SEK | 0.66% |
| 2021 Q1 | 2.84 Million SEK | -56.71% |
| 2020 Q4 | 6.57 Million SEK | 32751.66% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | 20.31 Thousand SEK | 0.0% |
| 2020 Q3 | 20 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.998% |
| AcouSort AB (publ) | 10.55 Million SEK | 99.782% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Alzinova AB (publ) | 270 Thousand SEK | 91.481% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.996% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.999% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 99.185% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 99.795% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.985% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 28.48 Million SEK | 99.919% |
| Kancera AB (publ) | 1.03 Million SEK | 97.778% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 98.858% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | 56.604% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.86% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.987% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 99.784% |
| OncoZenge AB (publ) | 3000.00 SEK | -666.667% |
| Saniona AB (publ) | 16.84 Million SEK | 99.863% |
| Simris Alg AB (publ) | 4.35 Million SEK | 99.472% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.99% |
| Xintela AB (publ) | 78 Thousand SEK | 70.513% |
| Ziccum AB (publ) | 3.74 Million SEK | 99.386% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 96.81% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | 5.54 Million SEK | 99.585% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | 82.308% |
| Intervacc AB (publ) | 8.01 Million SEK | 99.713% |
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.96% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.954% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 99.474% |
| Corline Biomedical AB | 25.03 Million SEK | 99.908% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 99.595% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.948% |
| Aptahem AB (publ) | 2.63 Million SEK | 99.126% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 70.13% |
| Fluicell AB (publ) | 3.33 Million SEK | 99.311% |
| Biovica International AB (publ) | 7.29 Million SEK | 99.684% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 98.088% |
| Abliva AB (publ) | 137 Thousand SEK | 83.212% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.96% |
| 2cureX AB (publ) | 155 Thousand SEK | 85.161% |
| I-Tech AB | 120.86 Million SEK | 99.981% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.983% |
| Cyxone AB (publ) | 5.14 Million SEK | 99.553% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 99.674% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 1.44 Million SEK | 98.406% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.968% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.935% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 98.428% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |